A key part of HSCI's mission is to help move discoveries out of the lab and into the market. One strategy is for our faculty to form startup companies based on their work. The following companies have been founded or co-founded by HSCI scientists:
HSCI Affiliate Faculty Albert Edge, PhD, is a scientific co-founder of Audion Therpaeutics, a private biopharmaceutical company dedicated to the discovery, development and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss.
HSCI Principal Faculty member Chad Cowan, PhD, is a scientific co-founder of CRISPR Therapeutics, a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure human genetic diseases.
Decibel Therapeutics is translating scientific advances, some of which originate from the lab of HSCI Affiliate Faculty member Albert Edge, in inner ear biology into novel therapies for people with hearing loss and tinnitus.
HSCI Principal Faculty members George Daley MD, PhD, and Yi Zhang, PhD, are scientific co-founders of Epizyme, a startup company striving to rewrite cancer therapy through targeted medicines for patients with unsolved diseases. It currently has a multiple clinical trials underway to understand the effects of tazemetostat study in patients with solid tumors.
HSCI Co-director David Scadden, MD, and Executive Committee chair Leonard Zon, MD, are both co-founders of Fate Therapeutics, a biopharmaceutical company focused on the discovery and development of adult stem cell modulators for patients with rare, life-threatening disorders--including certain hematologic malignancies, lysosomal storage disorders, and muscular dystrophies. A discovery from Zon's lab is now in Phase 2 clinical trials as a therapy that improves the success of cord blood transplants in adults.
Co-founded by HSCI Principal Faculty member Jeff Karp, PhD, Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue, including develping a small molecule that targets progenitor cells in the inner ear to treat chronic noise hearing loss.
Fulcrum Therapeutics is a startup with the aim to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease, and Affiliate Faculty members Bradley Bernstein, MD, PhD, and Jeannie Lee, MD, PhD are co-founders.
HSCI Principal Faculty member Jeffrey Karp, PhD, took a discovery from his lab to co-found Gecko Biomedical, a medical device company dedicated to the development and commercialization of novel biodegradable bio-inspired adhesives in the field of surgery, with a key focus on minimally invasive surgery. Karp is now chairman of the company's clinical and scientific advisory boards.
HSCI Principal Faculty member Connie Cepko, PhD, and Affiliated Faculty member Luk Vandenberghe, PhD, are both co-founders of the Paris-based GenSight Biologics. The biopharmaceutical company is dedicated to the development and commercialization of gene-therapy-based treatments of retinal degenerative diseases.
HSCI Executive Committee member Joe Benventre, MD, PhD, is a scientific co-founder of Goldfinch Bio, a company focused on discovering and developing precision therapies for patients with kidney disease.
Intellia Therapeutics is focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
HSCI Co-director Douglas Melton, PhD, Executive Committee member George Daley, MD, PhD, and Principal Faculty member Lee Rubin, PhD, together co-founded iPierian, which is developing therapies that inhibit the progression of Alzheimer's and other neurodegenerative diseases. Daley, Rubin, and Principal Faculty member Kevin Eggan, PhD, now act as scientific advisers.
LabMate, co-founded by HSCI Principal Faculty Amar Sahay, PhD, is a marketplace platform that rapidly connects biopharmaceutical companies and investment firms with scientists from top-tier research institutions for short-term consulting projects and full-time employment. LabMate's mission is to empower academic scientists to utilize their knowledge and technical skills to break the current scientific career bottleneck while also creating unprecedented value for the biopharmaceutical industry.
HSCI Co-director David Scadden, MD, and HSCI Principal Faculty member Derrick Rossi, PhD, are scientific co-founders of Magenta Therapeutics, which is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
HSCI Principal Faculty member Derrick Rossi, PhD, translated a discovery in his laboratory into a whole new class of drugs now being developed by Moderna Therapeutics. The Cambridge-based company, which Rossi co-founded, uses messenger RNA to produce human proteins inside patient cells, which offers an innovative way to deliver drugs to a patient.
Co-founded by HSCI Principal Faculty Rich Lee, MD, ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology and is improving clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.
Q-State Biosciences performs optical electrophysiology studies in human iPS-derived models of neuronal and cardiac diseases. The company combines the all-optical electrophysiology platform developed in the lab of HSCI Principal Faculty member Adam Cohen, PhD, with the stem cell-based disease modeling expertise of Principal Faculty member Kevin Eggan, PhD, to provide game-changing solutions to customers in pharma, academia, and to individual patients.
Quartet was founded based on groundbreaking scientific observations from co-founder and HSCI's Nervous System Diseases Program co-lead Clifford Woolf, MD, PhD, linking the tetrahydrobiopterin (BH4) synthesis pathway to chronic pain and inflammation. Quartet is uncovering the role that increased levels BH4 plays in human disease biology and developing therapies to safely reduce elevated BH4 levels.
Riparian, co-founded by HSCI Affiliate Faculty Guillermo Garcia-Cardena, PhD, is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today.
HSCI Executive Committee Chair Leonard Zon, MD, is co-founder of Scholar Rock, which is developing a new class of biologic therapies, called niche activators, to target disease-causing proteins. The therapeutics, based on growth activator research by Zon and other co-founder Harvard Medical School's Timothy Springer, PhD, have a wide range of disease applications including autoimmune diseases, fibrosis, and diseases of musculoskeletal systems.
Utilizing and building on scientific breakthroughs from the lab of HSCI Co-director Douglas Melton, PhD, Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections.
HSCI Affiliated Faculty member Biju Parekkadan, PhD, is a co-founder and director of Sentien Biotechnologies, which is developing new products that combine cell therapeutics with drug delivery systems to overcome the limitations of conventional cell administration.